Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action
Svetlana Miroshnichenko, Mariya Pykhtina, Anastasiia Kotliarova, Alexander Chepurnov, Anatoly Beklemishev · 2023
Read Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action by Svetlana Miroshnichenko, Mariya Pykhtina, Anastasiia Kotliarova, Alexander Chepurnov, Anatoly Beklemishev (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10745500.txt.
Description
Svetlana Miroshnichenko and co-authors published a 2023 study on a new form of interferon, a protein used against viruses and some cancers. Standard interferon works well but can harm cells and cause strong side effects. The team joined interferon to a blood protein called apolipoprotein A-I, hoping the joined form would be gentler and stay in the body longer.
The joined protein was made in yeast and cleaned to high purity. Tests showed it kept the full virus-fighting action of plain interferon against two viruses, yet harmed test cells less. In mice, the joined form stayed in the body about twice as long, which points to a safer drug that may need fewer doses.
Catalog record
| CREATOR | Svetlana Miroshnichenko, Mariya Pykhtina, Anastasiia Kotliarova, Alexander Chepurnov, Anatoly Beklemishev |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |